[
    [
        {
            "time": "2020-10-20",
            "original_text": "格隆汇港股聚焦(10.20)︱中国移动前三季净利816亿元，5G套餐客户达1.14亿户",
            "features": {
                "keywords": [
                    "中国移动",
                    "5G套餐",
                    "净利润",
                    "客户数"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "通信"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(10.20)︱中国移动前三季净利816亿元，5G套餐客户达1.14亿户",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "【浙商策略】以史为鉴，人民币升值期间的外资流入情况 | A股市场策略周报",
            "features": {
                "keywords": [
                    "人民币升值",
                    "外资流入",
                    "A股市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "外汇"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商策略】以史为鉴，人民币升值期间的外资流入情况 | A股市场策略周报",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "财华洞察 | 有备而来！25亿拿下金徽酒，投资大鳄复星如何谋定“酒局”？",
            "features": {
                "keywords": [
                    "复星",
                    "金徽酒",
                    "收购"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "财华洞察 | 有备而来！25亿拿下金徽酒，投资大鳄复星如何谋定“酒局”？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "丽珠试剂分拆上市冲击千亿蓝海、CRO第四家A+H企业将现……上市药企资本变局不断",
            "features": {
                "keywords": [
                    "丽珠试剂",
                    "分拆上市",
                    "CRO",
                    "A+H企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "丽珠试剂分拆上市冲击千亿蓝海、CRO第四家A+H企业将现……上市药企资本变局不断",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "板蓝根上热搜：香雪制药蹭热度 单凭概念炒作难撑长远发展",
            "features": {
                "keywords": [
                    "板蓝根",
                    "香雪制药",
                    "概念炒作"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "板蓝根上热搜：香雪制药蹭热度 单凭概念炒作难撑长远发展",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "揭秘主力资金出逃股连续5日净流出630股",
            "features": {
                "keywords": [
                    "主力资金",
                    "净流出",
                    "出逃股"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "揭秘主力资金出逃股连续5日净流出630股",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "【国盛策略】北上延续回流，配置盘大幅加仓——陆股通周监控第71期",
            "features": {
                "keywords": [
                    "北上资金",
                    "回流",
                    "加仓"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛策略】北上延续回流，配置盘大幅加仓——陆股通周监控第71期",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "复星医药：ORIN1001片获美国FDA药品临床试验批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "ORIN1001",
                    "FDA",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：ORIN1001片获美国FDA药品临床试验批准",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "研发周期可缩短至1年，德国新冠疫苗研发企业与复星医药携手参加进博会",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "复星医药",
                    "进博会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "研发周期可缩短至1年，德国新冠疫苗研发企业与复星医药携手参加进博会",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "白酒股逆势大涨背后：复星系加码布局 黄金股也来买醉",
            "features": {
                "keywords": [
                    "白酒股",
                    "复星系",
                    "加码布局"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "白酒股逆势大涨背后：复星系加码布局 黄金股也来买醉",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]